The FDA’s Center for Drug Evaluation and Research (CDER) has established the Emerging Technology Program to facilitate the integration of innovative methodologies in pharmaceutical product design and manufacturing. This initiative underscores the agency’s commitment to enhancing the efficiency and effectiveness of drug development processes.
By embracing cutting-edge technologies, CDER aims to streamline regulatory pathways and encourage industry stakeholders to adopt advanced manufacturing techniques. This shift not only supports the evolution of pharmaceutical practices but also addresses the growing demand for more efficient and reliable drug production.
The implications of this program are significant for B2B professionals in the pharmaceutical sector, particularly in regulatory, quality assurance, and supply chain management roles. As new technologies gain acceptance, organizations must adapt their strategies to remain competitive and compliant in an increasingly complex regulatory landscape.
Use the database as your supply chain compass →
